Immunovant
IMVT
32.04
-0.07
-0.22%
Immunovant
US · IMVT
#1790 by market cap
Listed 2017
32.04
-0.07
-0.22%
Live - 5344 symbols - heartbeat 426s ago
· 2026-10-08 07:11
Pre-market
31.00
-3.25%
After-hours
32.04
0.00%
Overnight
30.98
-3.31%
- Market cap
- 6.62B
- P/E (TTM)i
- -11.40
- P/Bi
- 9.00
- EPSi
- -2.77
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on IMVT?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
50.38 +57.2%
Price target rangecurrent 32.04
Low37.00
Avg50.38
High66.00
Buy 78%
Hold 22%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-26 | LifeSci Capital | -- | BUY | 53.00 |
| 2026-09-25 | Bernstein | -- | HOLD | 37.00 |
| 2026-09-24 | Truist Financial | -- | HOLD | -- |
| 2026-09-23 | LifeSci Capital | -- | BUY | 53.00 |
| 2026-09-23 | H.C. Wainwright | -- | BUY | 41.00 |
| 2026-09-21 | Piper Sandler | -- | BUY | 66.00 |
| 2026-08-11 | Stifel | -- | BUY | 57.00 |
| 2026-08-10 | H.C. Wainwright | -- | BUY | 41.00 |
| 2026-08-10 | J.P. Morgan | -- | BUY | 50.00 |
| 2026-08-07 | LifeSci Capital | -- | BUY | 53.00 |
| 2026-08-07 | Piper Sandler | -- | BUY | 66.00 |
| 2026-08-07 | BofA Securities | -- | BUY | 45.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 41.00 |
| 2026-08-07 | Oppenheimer | -- | BUY | 54.00 |
| 2026-08-04 | J.P. Morgan | -- | BUY | 50.00 |
| 2026-07-11 | LifeSci Capital | -- | BUY | 53.00 |
| 2026-07-09 | LifeSci Capital | -- | BUY | 53.00 |
| 2026-06-30 | Citi | -- | BUY | 61.00 |
| 2026-05-29 | Piper Sandler | -- | BUY | 66.00 |
| 2026-05-26 | Guggenheim | -- | BUY | 62.00 |
| 2026-05-26 | H.C. Wainwright | -- | BUY | 40.00 |
| 2026-05-26 | J.P. Morgan | -- | BUY | 47.00 |
| 2026-05-25 | Stifel | -- | BUY | 49.00 |
| 2026-05-23 | LifeSci Capital | -- | BUY | 45.00 |
| 2026-05-21 | Wells Fargo | -- | BUY | 45.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2027/Q1 | 2026-08-06 | -- | ±11.67% | +1.17% (in line) |
| 2026/Q4 | 2026-05-20 | -- | ±18.64% | +35.26% (beat) |
| 2026/Q3 | 2026-02-06 | -- | ±14.44% | +12.43% (in line) |
| 2026/Q2 | 2025-11-10 | -- | ±16.37% | +0.09% (in line) |
| 2025/Q2 | 2024-11-07 | -- | ±13.27% | -4.74% (in line) |
| 2022/Q4 | 2022-06-08 | -- | ±28.10% | -8.20% (in line) |
| 2022/Q1 | 2021-08-09 | -- | ±19.72% | +0.39% (in line) |
| 2021/Q4 | 2021-06-01 | -- | -- | -37.99% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:11:09 · For reference only, not investment advice and not tailored to your situation.